Diagnostics

Prioritizing the mechanistic understanding of AD to improve treatments

Longitudinal clinical outcomes of tau-PET-positive individuals

Clinical implementations of AlzoSure Predict

Predicting tau-PET signal in early Alzheimer’s disease using speech biomarkers

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer’s disease

Limitations of [18F]flortaucipir tau-PET imaging

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Understanding the effect of other diseases on blood biomarker levels in AD

Screening for delirium in individuals with dementia

Biomarkers of delirium incidence and severity

Biomarkers for risk assessment and early diagnosis of AD

Next steps in dementia biomarkers